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Understanding the dynamics of endogenous protein–protein interactions in complex net-
works is pivotal in deciphering disease mechanisms. To enable the in-depth analysis of
protein interactions in chromatin-associated protein complexes, we have previously devel-
oped a method termed RIME (Rapid Immunoprecipitation Mass spectrometry of Endogenous
proteins). Here, we present a quantitative multiplexed method (qPLEX-RIME), which inte-
grates RIME with isobaric labelling and tribrid mass spectrometry for the study of protein
interactome dynamics in a quantitative fashion with increased sensitivity. Using the qPLEX-
RIME method, we delineate the temporal changes of the Estrogen Receptor alpha (ERα)
interactome in breast cancer cells treated with 4-hydroxytamoxifen. Furthermore, we identify
endogenous ERα-associated proteins in human Patient-Derived Xenograft tumours and in
primary human breast cancer clinical tissue. Our results demonstrate that the combination of
RIME with isobaric labelling offers a powerful tool for the in-depth and quantitative char-
acterisation of protein interactome dynamics, which is applicable to clinical samples.
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Deciphering the role and the organisation of dynamicallyregulated protein networks is critical for the accuratemolecular characterisation of biological systems1. Over
the last decade, the advancements made in mass spectrometry-
based proteomics have enabled the rapid analysis of complex
protein samples obtained from co-immunoprecipitation assays,
providing a powerful tool for the study of protein interactions
and protein complexes2. In this regard, the first systematic efforts
to generate human protein interactome maps using yeast two-
hybrid3–5 have been recently complemented by studies utilising
large-scale Affinity Purification followed by Mass Spectrometry
analysis (AP-MS)6,7. Additionally, the integration of AP-MS with
quantitative approaches has enabled the study of stoichiometric
changes in protein complexes8. More recently, the use of chemical
crosslinking combined with mass spectrometry has provided
information about endogenous protein assemblies in a proteome-
wide scale9.
Gene regulation relies on the coordinated action of transcrip-
tion factors and co-regulator complexes that control transcrip-
tional activation at promoters or enhancers. To gain insight into
the complex interactions between such regulators, the combina-
tion of Chromatin Immunoprecipitation (ChIP) with mass
spectrometry has been used to study the composition of
chromatin-associated complexes10–12. In line with this strategy
we have previously developed RIME (Rapid Immunoprecipitation
Mass spectrometry of Endogenous proteins)13, a method which
has several advantages for the analysis of protein interactomes14.
RIME provides a sensitive and rapid approach for the identifi-
cation of protein complexes from low amounts of starting
material and importantly involves purification of endogenous
protein, rather than the use of exogenous tagged approaches.
In the present study, we have established a modified RIME
assay to monitor the dynamics of chromatin-associated com-
plexes using a quantitative multiplexed workflow (quantitative
Multiplexed Rapid Immunoprecipitation Mass spectrometry of
Endogenous proteins or qPLEX-RIME). Specifically, we combine
RIME with isobaric labelling using Tandem Mass Tags (TMT-
10plex)15,16, peptide fractionation and MultiNotch MS3 analy-
sis17. This combination allows the simultaneous analysis of
multiple conditions and biological replicates with high sensitivity
in a single experiment. Additionally, we have developed a data
analysis workflow termed quantitative Multiplexed analyzer
(qPLEXanalyzer) that permits statistical analysis of the quanti-
tative interactome data and the identification of differential
interactions.
As a proof-of-concept, we apply the qPLEX-RIME method to
discover the temporal changes of Estrogen Receptor alpha (ERα)
interactors in breast cancer cells treated with 4-hydroxytamoxifen
(OHT) and to identify the ERα interactome in human patient-
derived xenograft (PDX) tumours and in human breast cancer
tissues. Our data demonstrate that the qPLEX-RIME method
combines multiplexity with quantitative accuracy and increased
sensitivity, to enable the in-depth characterisation of dynamic
changes in chromatin-associated protein complexes in vitro and
in vivo.
Results
The qPLEX-RIME workflow. The qPLEX-RIME approach
combines the RIME method13,14 with multiplex TMT chemical
isobaric labelling15,16 to study the dynamics of chromatin-
associated protein complexes. The workflow starts with a two-
step fixation procedure using disuccinimidyl glutarate (DSG) and
formaldehyde (FA) that has been previously applied in combi-
nation with ChIP assays to capture transient interactions more
efficiently12,18. A specific antibody against the target protein is
used for immunoprecipitation, followed by proteolysis, TMT-
10plex peptide labelling and fractionation. The main steps of the
qPLEX-RIME method are shown in Fig. 1. The main utility of the
qPLEX-RIME method is the quantification of changes in the
composition of protein complexes in response to cell perturbation
and/or in variable genomic backgrounds (e.g. different cell lines
or mutated conditions) using multiple biological replicates in a
single experiment. Also proteins that are significantly and speci-
fically associated with the bait protein can be discovered in the
same analysis using appropriate negative controls, such as IgG
pull-downs. For the downstream data analysis, we have developed
a comprehensive bioinformatics workflow (qPLEXanalyzer) that
includes data processing, visualisation, normalisation and differ-
ential statistics . In addition to the qPLEXanalyzer R package, the
complete qPLEX-RIME and full proteome data sets of this work
are included in the qPLEXdata R package. Both packages can be
found at (https://doi.org/10.5281/zenodo.1237825) and a detailed
description of the pipeline and the applications is provided in
Supplementary Notes 1 and 2.
Characterisation of the ERα interactome in MCF7 cells. We
first applied qPLEX-RIME to assess whether we could successfully
identify the ERα interactome in asynchronous MCF7 breast
cancer cells. To this end, we performed ERα qPLEX-RIME pull-
downs in five independent biological replicates. An equal number
of matched IgG control samples were prepared. In this experi-
ment we used single crosslinking with FA, to permit a compar-
ison with previously published approaches13. In addition to the
qPLEX-RIME, we included a standard non-quantitative ERα
RIME experiment with matched IgG controls (Supplementary
Data 1).
The qPLEX-RIME raw data processing quantified 2955
proteins across the multiplexed set of all positive and negative
samples at peptide false discovery rate (FDR) <1% (Supplemen-
tary Data 2). To test the efficiency of the method in capturing and
quantifying previously described ERα-associated proteins, we
compiled a list of known ERα interactors from BioGRID19 and
STRING20 resources. For BioGRID, we used only a subset of 386
proteins identified by high-throughput assays that are similar to
the approach used here and for STRING we used only
experimental associations (383 proteins, score > 200). Note-
worthy, only 37 proteins were common between the two
reference subsets. The qPLEX-RIME method identified 295
(76%) and 171 (45%) of the known ERα-associated proteins
from BioGRID and STRING, respectively, of which 225 (58%)
and 154 (40%) showed positive enrichment at adj. p-value < 0.1
(Limma moderated t-test) (Fig. 2a). Specifically, we found known
co-regulators (e.g. EP300, NCOA3, CBP, NRIP1, TRIM24,
GREB1, RARα, NCOR2 and HDACs13,21–25), ERα-associated
pioneer factors (e.g. FOXA126 and AP-2γ27), and putative pioneer
factors (e.g. GATA-328) with significant enrichment in the ERα
samples (Fig. 2b).
ERα was one of the most significantly enriched proteins
identified with 19 unique peptides (Fig. 2c), which is consistent
with previously published ERα RIME experiments14. A compar-
ison between the non-quantitative RIME and the qPLEX-RIME
data showed that 302 of the 323 (93%) proteins identified as
ERα-specific in the non-quantitative ERα-RIME pull-down
analysis were also identified by qPLEX-RIME with significant
enrichment over the IgG controls (mean fold-change of 2.5).
Notably, the application of qPLEX-RIME achieved overall better
peptide coverage for the overlapping ERα-associated proteins
compared to the non-quantitative RIME method (Fig. 2d).
Additionally, qPLEX-RIME identified 124 more known BioGRID
and STRING interactors compared to the non-quantitative RIME
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analysis (175 proteins > 2-fold and adj. p-value < 0.01 (Limma
moderated t-test) in qPLEX-RIME versus 51 proteins in non-
quantitative RIME). Importantly, using the qPLEX-RIME we
identified a number of novel ERα-associated candidate proteins.
We validated the interactions of CBX3 (HP1γ), NIPBL and
FOXK1 with ERα, using Proximity Ligation Assay (PLA)29
(Supplementary Fig. 1a). A GFP negative control was used to
moninor for non-specific interactions (Supplementary Fig. 1b).
Treatment of the MCF7 cells with the Selective ERα Degrader
(SERD) Fulvestrant30 (Supplementary Fig. 2) disrupted the above
interactions demonstrating the specificity of the PLA assay and
validating the interactors discovered by qPLEX-RIME (Supple-
mentary Fig. 1a and c).
To test whether our quantitative pipeline can be widely used to
study interactors of different bait proteins, we performed qPLEX-
RIME experiments on three additional factors following the same
experimental design as above. For these and all subsequent
experiments described in this study, we adopted the double
crosslinking approach as a comparison between single and double
crosslinking for ERα qPLEX-RIME data showed that the latter
increases the pull-down efficiency of known and previously
validated ERα interactors, including FOXA1, NR2F2 and NCOR2
(Supplementary Fig. 3a and Supplementary Data 3).
Firstly, the qPLEX-RIME method was applied to explore the
interactome of CBP (CREB-binding protein) and NCOA3 (SRC-
3); two well-characterised co-activators of nuclear receptors31.
We identified 1437 and 1135 proteins for CBP and NCOA3,
respectively, in the two multiplexed sets of bait and IgG pull-
downs at peptide FDR < 1% (Supplementary Data 4 and 5). Both
bait proteins were highly enriched in the target pull-downs
compared to the IgG controls (CBP:log2fold-change= 3.2 and
NCOA3:log2fold-change= 3.39) with a high number of unique
peptides (44 unique peptides for CBP and 36 unique peptides for
NCOA3) (Fig. 3a, b). Known interactors of CBP and NCOA3
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were identified including EP300, p160 co-activators, arginine
methyltransferases and the ERα complex31 (Fig. 3a, b). We also
identified several members of the SWI/SNF chromatin remodel-
ling complex, such as SMARCA4 (BRG1), SMARCE1 (BAF57),
SMARCB1 (BAF47) and SMARCC2 (BAF170). Additionally, in
the CBP qPLEX-RIME experiment we captured the association of
CBP with the transcription factor JunB32, as well as with subunits
of the mediator complex33, which are known to associate with
enhancer regions as well. Interestingly, in addition to other co-
activators, we also found a strong enrichment of co-repressors
such NCORs and HDACs in both data sets. This suggests that
both co-activators and co-repressors are part of the same
complex, which is consistent with previous findings demonstrat-
ing extensive co-localisation of co-repressors and co-activators by
ChIP-seq34.
Secondly, we studied the interactome of phospho-RNA
polymerase II (POLR2A) using an antibody that recognises the
phosphorylated serine-5, which serves as a platform for assembly
of factors that regulate transcription initiation, elongation,
termination and mRNA processing35. We identified 1442
proteins across all multiplexed samples (Supplementary Data 6)
and the bait protein was one of the top enriched proteins
(log2fold-change= 4.2), identified with 96 unique peptides
(Fig. 3c). A list of known polymerase II-associated factors were
also observed, such as subunits of the SWI/SNF complex, proteins
of the mediator complex, initiation and elongation factors36,37
that are highlighted in Fig. 3c. A comparison of the interactomes
of the four bait proteins (ERα, CBP, NCOA3 and POLR2A)
showed significant numbers of uniquely identified interactors as
well as partial overlap (Supplementary Fig. 3b). To examine
whether the overlapping proteins are more likely due to the
common underlying biology of the four baits rather than
technical bias, we made a venn diagram using a random selection
of proteins identified in the four qPLEX-RIME experiments,
without considering enrichment relative to the IgG pull-downs
(Supplementary Fig. 3c). This analysis showed a smaller number
of proteins in the intersection of the four bait proteins indicating
small contribution of technical factors to the observed overlap.
Taken together, our data demonstrate a gain in sensitivity
using the qPLEX-RIME method that can lead to the identification
of interacting proteins with statistical robustness and can be
widely used for the characterisation of different interactomes.
Study of ERα complex dynamics upon OHT treatment. To
investigate the dynamics of the ERα complex assembly upon
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treatment with the Selective Estrogen Receptor Modulator
(SERM) 4-hydroxytamoxifen (OHT), we performed three
qPLEX-RIME experiments (3 × 10plex) using independently
prepared biological replicates. MCF7 cells were crosslinked after
treatment with 100 nM OHT for 2 h, 6 h and 24 h or after 24 h of
vehicle (ethanol) treatment. Two biological replicates of each
condition were included in each experiment, resulting in a total of
six replicates per time point. Additionally, MCF7 cells were
treated with OHT or ethanol and crosslinked after 24 h treatment
in each experiment to be used for control IgG pull-downs, to
enable discrimination of non-specific binding.
To confirm that the drug treatment was successful, we
performed RNA-seq analysis of six biological replicates using
matched OHT treated samples. The mRNA data revealed
transcriptional repression of a number of known ERα target
genes at 6 h and 24 h, confirming the response to the drug
treatment. Specifically, at 24 h treatment the expression of PGR,
PDZK1, TFF1, AREG, PKIB, SIAH2, MYB, HEY2, FOS, GREB1
and TFF338–43 was significantly inhibited compared to the vehicle
treatment (log2Fold-Change <−0.5, adj. p-value < 0.05, Limma
moderated t-test) (Supplementary Fig. 4a and Supplementary
Data 7).
MultiNotch MS3 analysis of the qPLEX-RIME samples
quantified 1105 proteins (FDR < 1%) across all three replicate
experiments. Of these, 412 proteins were significantly enriched in
ERα pull-downs compared to IgG samples (log2Fold-Change > 1,
adj. p-value < 0.01, Limma moderated t-test) (Supplementary
Data 8). Total ERα levels changed upon OHT treatment
(Supplementary Fig. 4b), indicating that altered levels of antigen
may influence the amount of purified proteins. Our data showed
that this resulted in a significant dependency of the quantified
proteins on the amount of ERα pulled down (Supplementary
Fig. 5a). To correct for this effect, we applied a linear regression
approach15,44 using the ERα profile as the independent variable
and the profile of any other protein as the dependent variable.
The advantage of this approach is that proteins with strong
dependency on the target protein are subjected to significant
correction, whereas proteins with small dependency on the target
protein are only slightly corrected. Two such examples, of known
ERα interactors before and after correction are shown in
Supplementary Fig. 5b. Finally, using the quantification values
corrected for the abundance of ERα, we found 249 specific
proteins with altered profile in the interactome in at least one
time point (|log2Fold-Change| > 0.5, adj. p-value < 0.05, Limma
moderated t-test) allowing for a comprehensive mapping of the
dynamic organisation of the ERα complex in response to OHT
treatment.
Dissociation and recruitment of co-factors upon OHT
treatment. We next interrogated the significant changes observed
in the ERα interactome at each time point during OHT-mediated
growth inhibition. After 2 h treatment with OHT, a significant
loss of 12 proteins was observed including known ERα co-acti-
vators, such as NCOA3 (AIB1/SRC-3) and CREBBP (CBP)
(Fig. 4a). These proteins have been associated with histone
acetylation and activation of gene transcription23,45 and their loss
in the ERα interactome upon OHT treatment is consistent with
previous studies showing that OHT binding blocks access of co-
activators46. We also observed a significant loss of the interaction
between ERα and NRIP1 (RIP140) protein. NRIP1 can act as a
corepressor or as a coactivator47 with previous evidence
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suggesting that NRIP1 is required for ERα-complex formation
and ERα-mediated gene expression47. The quantification profile
of these key ERα co-activator proteins across all biological
replicates is shown in Fig. 4b. Furthermore, OHT treatment
resulted in the loss of GREB1 and its paralog gene product
GREB1L. Loss of GREB1 upon OHT treatment has been pre-
viously described13, but here we report the loss of both proteins
simultaneously.
After 6 h treatment with OHT, 237 specific interactors showed
significant enrichment (log2Fold-Change > 0.5, adj. p-value
< 0.05, Limma moderated t-test) compared to the vehicle
treatment, whilst NCOA3, NRIP1, GREB1 and GREB1L
remained at decreased levels in the interactome (log2Fold-
Change < -0.5, adj. p-value < 0.05, Limma moderated t-test)
(Fig. 4a). Notably, there was an enrichment in the recruitment
of several components of the NuRD (Nucleosome Remodelling
and Deacetylase) complex, e.g. HDAC1/224,48 and the signature
components MTA1/224,48, as well as an enrichment of the
co-repressor NCOR2 (SMRT)25,49 (Fig. 4b). Consistently, NURD
complex and NCOR2 has been previously shown by ChIP to be
recruited to promoter regions of ERα target genes following OHT
treatment23,24. Additionally, we found enriched subunits of the
ATP-dependent chromatin remodelling complex SWI/SNF,
which is known to regulate both gene activation and gene
repression50,51. Detected components included SMARCC2
(BAF170), SMARCE1 (BAF57) and SMARCA4 (BRG1) (Fig. 4b).
SMARCA4 protein, which was previously shown to be required
for repression of ER-mediated transcription50, was one of the top
enriched SWI/SNF proteins. The loss of NCOA3 and CBP at 2 h
and the enrichment of SMARCC2 (BAF170) and HDAC1 at 6 h
was validated with PLA assays (Supplementary Fig. 6a and b).
At 24 h we observed an almost complete restoration of the ERα
complex, with the exception of the NCOA3, NRIP1 and GREB1
proteins, which were still decreased (log2Fold-Change <−0.5, adj.
p-value < 0.05, Limma moderated t-test) (Fig. 4a). Taken together,
our results indicate that the inhibitory effect of OHT peaks at 6 h,
where ATP-dependent remodelling and corepressor complexes
may coordinate to create a transcriptionally inactive chromatin
environment.
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Identification of net changes in the ERα complex. Our data
suggest that treatment of MCF7 cells with OHT triggers sig-
nificant changes in the composition of ERα interactome. To
assess whether the changes identified by the qPLEX-RIME ana-
lysis are specific changes in interactions or result from changes in
total protein levels, we performed timecourse whole proteome
quantification in matched samples under the same conditions
(vehicle, 2 h, 6 h and 24 h, four biological replicates each) (Sup-
plementary Data 9). We confirmed the OHT up-regulation of
ERα protein levels (log2Fold-Change: 2 h 0.21, 6 h 0.5 and 24 h 1),
which was not due to an increase in gene transcription. This is
consistent with previous reports demonstrating increased ERα
stability in the presence of OHT52. A comparison between the
qPLEX-RIME results and the total proteome data confirmed that
the changes detected in the ERα complex upon OHT treatment
represent changes in protein recruitment as the respective total
protein and mRNA levels remained unchanged (Fig. 5a). GREB1
was the only ERα interactor with decreased mRNA and total
protein levels at 24 h treatment. This is consistent with GREB1
being an ERα target gene13,43 and explains the decreased asso-
ciation between ERα and GREB1 at this late time point.
Downstream k-means clustering of the most variable proteins
(adj. p-value < 0.05, Limma moderated t-test) across the three
time points in the total proteome, identified clusters of up- and
downregulated proteins (Fig. 5b). Gene Set Enrichment Analysis
of the clusters, performed in Perseus software53, displayed an
overrepresentation of genes related to estrogen response and
tamoxifen resistance (Fig. 5c). Our findings also revealed the
downregulation of proteins involved in cell cycle54 (Supplemen-
tary Fig. 7a), in line with the antiproliferative effects of OHT24.
Overall, significant changes in gene expression were observed
already at 6 h coinciding with pronounced changes in the ERα
interactome. As expected, the most significant changes in the total
proteome were observed at the later time point (24 h). These
results confirm that shuffling of ERα-associated proteins is not
typically due to global changes in protein levels. The low mRNA-
to-protein correlation at 2 h and 6 h and the respective strong
correlation at 24 h are shown in Supplementary Fig. 7b and c. We
conclude that our qPLEX-RIME data in combination with the
total proteome measurements delineate both the local molecular
events in the ER interactome and the associated downstream
global effects.
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Application of qPLEX-RIME in clinical tumour material. To
test whether qPLEX-RIME can be used to capture chromatin-
associated protein–protein interactions in cancer specimens, we
conducted an ERα qPLEX-RIME experiment using three inde-
pendent ER positive human PDX tumours (HCI-003, HCI-005,
HCI-006) that have been previously described55. Cryosections
(30 µm) of each tumour were double-crosslinked and each
tumour was split into ERα and matched IgG pull-downs (Fig. 6a).
The MultiNotch MS3 analysis identified 2319 proteins (FDR <
1%) across all multiplexed samples with highly reproducible
profiles (Supplementary Fig. 8a and Supplementary Data 10).
This analysis successfully recovered and quantified ERα
(log2Fold-Change= 1.72, adj. p-value= 0.026, Limma moderated
t-test, unique peptides= 3) using an unbiased mass spectrometry
approach in tissue. In addition, many validated and known ERα
interactors were discovered from the qPLEX-RIME conducted in
PDX material, including CBP23,56, NCOA256, HDAC124,
GREB113, SMARCE1 (BAF57)51, SMARCA4 (BRG1)45 and
NCOA5 (CIA)57 (Supplementary Fig. 8b). Sequence analysis of
the qPLEX-RIME data showed that 60% of the significant inter-
actors were identified with at least one unique human peptide (i.e.
a peptide that does not align to the mouse proteome), indicating
that the proteins identified above were primarily from the human
cancer cells. Consistently, the tumour samples showed high
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cellularity and positive staining for human ERα exclusively in the
cancer cells and not in the stroma (Supplementary Fig. 8c ).
Prompted by the successful application of qPLEX-RIME in
PDX tumours we sought to test the sensitivity of our method in
human cancer clinical tissues, collected from surgery. To this end,
we performed an ERα qPLEX-RIME experiment in five
independent human breast cancer tumours (ERα positive, PR
positive, Her2 negative and Grade2/Grade3). Approximately
60 sections (30 µm) were obtained per sample, which were
double-crosslinked and split for ERα and matched IgG pull-downs
(Fig. 6a). The analysis successfully recovered ERα with excellent
coverage (17 unique peptides), as well as 2191 proteins (FDR <
1%) that were quantified in all samples combined (Supplementary
Data 11). These included well-described ERα interactors such as
FOXA1, GATA3, GREB1, EP300, CBP, HDACs, NCORs and
NCOA2 and subunits of the SWI/SNF complex (Fig. 6b). The
enrichment of several ERα interactors in the bait samples
compared to IgG control samples is illustrated in Fig. 6c.
Our data highlights the method’s sensitivity and ability to
identify endogenous protein networks from heterogeneous
human tumour samples. Importantly, we report the identification
of interactors from human tumour tissue material in an unbiased
manner.
Discussion
Here, we describe qPLEX-RIME, a proteomic method which
enables comprehensive mapping of endogenous protein inter-
actomes with high sensitivity and statistical robustness. The
qPLEX-RIME approach integrates the well-established RIME
immunoprecipitation method with advanced high-resolution
quantitative multiplexed mass spectrometry analysis. The
method can be utilised to discriminate enriched bona fide binding
partners from contaminant proteins and to delineate the
dynamics of chromatin-associated protein complexes with in-
depth protein detection, reproducible quantification and
increased sample throughput. The filtering criteria for the
prioritisation of the best candidates depend on the type of
experiment and the biological question. For bait proteins where
very little is known about their interactome, we recommend the
use of more stringent specificity criteria in terms of enrichment
fold-change, p-value and number of unique peptides in combi-
nation with additional filtering based on functional annotations.
When the focus is on the dynamic changes of interactomes, the
prioritisation of the candidates mostly relies on their robust
quantitative profiling across different conditions.
The multiplexed analysis of our pipeline eliminates the need to
compare multiple data obtained by individual LC-MS runs,
thereby increasing the quantification coverage in very low abun-
dant protein interactors that are stochastically captured between
independent replicate runs58. The ability to combine the labelled
peptides derived from multiple samples increased the sensitivity of
the method and enabled the characterisation of the ERα inter-
actome in clinical tumours. Whilst interactors have previously
been detected from clinical material, this required targeted mass
spectrometry-based approaches and has not been done in an
unbiased manner before13. Additionally, the use of isobaric
labelling resolves the difficulties encountered with cell lines that
are not compatible with stable-isotope labelled culture media and
provides a means for quantitative analysis for clinical samples that
are not amenable to in vivo isotopic labelling techniques.
Importantly, our isobaric-labelling data demonstrated high
reproducibility with previously published SILAC data13 (Supple-
mentary Fig. 7d), confirming the accurate quantification obtained
by the MultiNotch MS3 level mass spectrometry analysis.
Here, we focused on ERα, the major driving transcription
factor in luminal breast cancer56, which can be targeted by
tamoxifen, a drug used for the treatment of ER+ breast cancer59.
Although many ERα interactors involved in ER-mediated gene
expression have been discovered23,45 our knowledge about their
relevance at the tissue level and the impact of tamoxifen on their
global association with ERα remains limited. The quantitative
data obtained by the qPLEX-RIME experiments has provided us
with a list of ERα-associated proteins with significant enrichment
over the IgG samples. These include transient, indirect or weak
interactions, as it is known that ERα associates with a number of
different co-activators rapidly in a cyclic fashion23,45. As such the
final readout of the crosslinking-based qPLEX-RIME method
represents the sum of these interactions. Among these, we vali-
dated the interactions between ERα and three proteins; namely
CBX3, NIPBL and FOXK1. CBX3 protein is a member of the HP1
protein family, a group of proteins that have been implicated in
gene regulation, DNA replication and nuclear architecture60,
whereas NIPBL is a core subunit of the highly conserved protein
complex cohesin that has an important role in chromatin struc-
ture, gene expression, and DNA repair61. The transcription factor
FOXK1 belongs to the forkhead family and has an important role
in tumorogenesis62,63. These findings demonstrate that the gain
in sensitivity obtained by qPLEX-RIME can reveal novel ERα
interactors. Collectively, we identified a compendium of 253
proteins with consistent presence in all MCF7 data sets (Fig. 7).
Importantly, our data show that the vast majority of these ERα-
associated proteins (83%) can now be studied either in PDX or in
human clinical tissues validating the relevance of these factors
in vivo. Additionally, our qPLEX-RIME data on three additional
factors, the CREBBP, NCOA3 and the phosphorylated form of
POLR2A, highlight the wide applicability of our pipeline.
The application of qPLEX-RIME targeting ERα at multiple
time points after OHT treatment, revealed a dynamic change in
ERα co-regulators following drug treatment recapitulating and
expanding the existing knowledge of OHT mechanism. After 2 h
OHT treatment, we observed a loss of important transcriptional
co-activators, such as NCOA3 and CBP, whereas at 6 h we
observed enrichment on the recruitment of two well-conserved
chromatin remodelling complexes, namely the NuRD and the
SWI/SNF complex. This coincided with the enrichment of the
basal corepressor NCOR2, which assists in the recruitment of
HDAC proteins64. At the latest time point of 24 h, we observed a
restoration of the ERα complex, which may be linked to the half-
life of OHT. The exceptions were NRIP1, GREB1 and NCOA3.
Interestingly, NCOA3 is amplified in breast cancer22 and its
expression levels have been associated with the effectiveness of
tamoxifen treatment65. Further, ChIP-seq analysis has revealed
that a number of binding sites of NCOA3 are associated with
genes with a predictive value for breast cancer patient outcome56,
supporting an important role of this co-regulator in tamoxifen
response.
Our timecourse data indicate a switch between activation and
repression of transcription in response to OHT treatment. This
transition engages a two-step process with the immediate loss of
co-activators, followed by the recruitment of co-repressors and
ATP-chromatin remodelling complexes that may act coopera-
tively or in a sequential manner to accomplish transcriptional
repression. The integration of qPLEX-RIME data with global
protein and mRNA analysis provides a comprehensive view of the
activity of a transcription-associated complex over time. A pro-
posed model of OHT mechanism is depicted in Supplementary
Fig. 9.
The qPLEX-RIME method can be used to monitor any
dynamic changes of interest and importantly can be applied to
clinical samples to study tumour evolution, treatment response or
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numerous other biological and clinical questions. It provides a
robust tool for the quantitative analysis of complexes that can be
applied to generate comprehensive endogenous protein–protein
interaction maps.
Methods
Cell lines and cell treatments. ERα-expressing MCF7 breast cancer cells were
cultured in Dulbecco’s Modified Eagle Medium DMEM (Gibco, Thermo Scientific,
Leicestershire, UK, ref. 41965-239). Media was supplemented with 10% foetal
bovine serum (FBS), 50 U/ml penicillin, 50 μg/ml streptomycin and 2 mM
L-glutamine. MCF7 cells were obtained from ATCC and they were tested for
mycoplasma contamination. Also, the MCF7 cells were genotyped by short-tandem
repeat genetic profiling using the PowerPlex_16HS_Cell Line panel and analysed
using Applied Biosystems Gene Mapper ID v3.2.1 software by the external provider
Genetica DNA Laboratories (LabCorp Specialty Testing Group). For the cell
treatments, 4-Hydroxytamoxifen (Sigma-Aldrich, #HG278) or Fulvestrant (Sell-
eckchem, #S1191) were used at final concentration 100 nM.
Whole cell lysate preparation and western blot analysis. Cell pellets were
reconstituted in 100 μl RIPA buffer (Thermo Scientific, #89901) that was supple-
mented with protease inhibitors (Roche). 25 μg protein from each sample was
loaded on the gel (Invitrogen 4–12%) and the Precision Plus, ProteinTM dual
colour Standards Protein molecular weight marker (Bio-Rad, #161-0974) was used
for the determination of protein sizes. The proteins were transferred onto a
nitrocellulose membrane using the iBlot® 2 Dry Blotting System (Invitrogen) fol-
lowed by one hour blocking using Odyssey® Blocking Buffer (Li-Cor,
927-40000). The membrane was immunoblotted with ERα antibody (Novocastra
#6045332, 1:100) and beta-actin (Cell signalling #4970, 1:1000). Detection of the
ER was achieved using the IRDye® 800 CW Goat anti-Mouse (926-32210, Li-Cor
Biosciences) diluted to 1:5000, while the loading control was detected using the
IRDye 680LT Goat anti-Rabbit (926-68071, Li-Cor Biosciences) diluted to 1:15000.
All antibodies were diluted in Odyssey Buffer contained 0.1% Tween. Supple-
mentary Fig. 10 shows the uncropped scan of the blot.
RNA-seq analysis. Cells were washed twice with cold Phosphate buffered saline
(PBS) and harvested using 350 μl of lysis buffer (RLT). Total RNA was extracted
using the RNeasy® kit (Qiagen, #74106) according to the manufacturer’s instruc-
tions. The extracted RNA was quantified using a NanoDrop® ND-1000
Spectrophotometer (Thermo Scientific). For the library preparation, the Illumina
TruSeq Stranded mRNA Library Prep Kit High Throughput was used according to
the manufacturer’s instructions and two lanes of 50 bp single-end reads were run
on HiSeq 4000. Reads were aligned to the human genome version GRCh37.75
using TopHat v2.1.066. Read counts were obtained using feature Counts function in
Subread v1.5.267 and read counts were normalised and tested for differential gene
expression using the DESeq2 workflow68. Multiple testing correction was applied
using the Benjamini–Hochberg method.
RIME analysis. MCF7 cells (2 × 106) were grown in complete media. The media
was replaced with PBS containing 1% FA (Thermo #28908) and crosslinked for 10
min. For the double crosslinking cells were incubated in PBS containing 2 mM
DSG (disuccinimidyl glutarate- Santa Cruz Biotechnology, #sc-285455A) for 20
min followed by incubation in 1% FA for 10 min. Crosslinking was quenched by
adding glycine to a final concentration of 0.1 M. For the performance of RIME
experiments, 50 μl of Dynabeads® Protein A (Invitrogen) and 5 μg of specific
antibody were used for each sample. The antibodies used were: Rabbit polyclonal
ERα antibody (Santa Cruz, sc-543), rabbit polyclonal SRC3 antibody (Bethyl
laboratories, A300-347A), rabbit polyclonal CBP antibody (Diagenode,
C15410224), rabbit polyclonal RNA polymerase II (phospho S5) antibody (Abcam,
ab5131) and rabbit IgG antibody (Santa Cruz, sc-2027 or Abcam, ab171870). For
nuclear extraction the cell pellet was resuspended in LB1 buffer (50 mM HEPES-
KOH (pH 7.5), 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40 and 0.25%
Triton X-100) followed by rotation mixing for 10 min at 4 °C. Then, nuclei were
pelleted and resuspended in LB2 buffer (10 mM Tris-HCL (pH 8.0), 200 mM NaCl,
1 mM EDTA and 0.5 mM EGTA) and rotated at 4 °C for 5 min. The samples were
resuspended in LB3 buffer (10 mM Tris-HCl (pH 8), 100 mM NaCl, 1 mM EDTA,
0.5 mM EGTA, 0.1% Na-deoxycholate and 0.5% N-lauroylsarcosine). Chromatin
was sheared by sonication (Diagenode) to produce DNA fragments of 100–1,000
bp. The bead-bound antibody and chromatin were incubated overnight at 4 oC.
The next day the beads were washed 10 times with 1 ml ice-cold RIPA buffer and
twice with 500 μl 100 mM AMBIC (ammonium bicarbonate).
Proximity ligation assay. Cells were fixed and permeabilised by the addition of
ice-cold methanol (−20 °C) for 3 min followed by three washing steps with cold
PBS. PLA was carried out according to manufacturer’s instructions (Sigma Aldrich,
#DUO92007). The following primary antibodies were used for the PLA assay: ERα
(Santa Cruz, sc-543 or sc-8002, 1:250) HP1γ (Santa Cruz, sc-365085, 1:400), NIPBL
(Santa Cruz, sc-374625, 1:200), FOXK1 (Santa Cruz, sc-373810, 1:200), GFP
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(Abcam, ab1218, 1:200), NCOA3 (Bethyl Laboratories, A300-347A, 1:200), CBP
(Bethyl Laboratories, A300-363A, 1:200), BAF170 (Santa Cruz, sc-17838, 1:200),
HDAC1 (Santa Cruz, sc-81598, 1:200) and the incubation on the coverslips was
performed for 1 h at 37 °C. For the single PLA recognition experiment two ERα
antibodies (Santa Cruz, sc-543, 1:800 and Invitrogen, MA5-13191, 1:1200) were
used in combination. The secondary proximity probes (Sigma Aldrich, Rabbit-
PLUS, #DUO92002 and Mouse-MINUS, #DUO92004) were incubated for 1 h at
37 °C. The Leica DFC340FX microscope was used and images were captured with
Leica Imaging software. DAPI and PLA fluorescence were captured at high reso-
lution for a total of 8 separate observation fields. Cell numeration and PLA
labelling were carried out using Image J software. Cells and red PLA dots were
counted using the ‘Analyze Particles’ function. For each condition at least 200 cells
were imaged and analysed. Then, the average value of number of spots per nucleus
was calculated. All statistical analyses were carried out by performing Student’s t-
test.
Immunofluorescence. Cells were fixed and permeabilised with ice-cold (−20 °C)
methanol for 3 min and after fixation cells were blocked in PBS-5 % (w/v) Bovine
Serum Albumin (BSA) (Sigma-Aldrich) for 30 min at room temperature. The
primary ERα antibody (Santa Cruz, sc-543, 1:250) was diluted in blocking solution
(PBS-5 % (w/v) BSA) and incubated on coverslips for 1 h at 37 °C. Afterwards, the
coverslips were washed four times in washing buffer (PBS-0.5% Tween). Secondary
antibody conjugated to Alexa Fluor 488 (Invitrogen, #A-21206, 1:500) was diluted
in blocking solution and incubated on coverslips for 1 h at 37 °C in the dark.
Coverslips were then washed again three times in washing buffer and once in PBS.
PDX propagation and tissue collection. Viably frozen PDX tumour tissue was
propagated in immune-compromised mice. Briefly, 1 mm3 tumour pieces were
implanted into the 4th mammary pad of NSG mice. All mice were supplemented
with estrogen, using silastic E2 pellets (made in-house) inserted into the dorsal
scruff. Twice weekly standard monitoring and tumour measurement was con-
ducted. Once tumours reached appropriate size, ~1000 mm3, mice were sacrificed
by cervical dislocation under deep, isoflurane-induced anaesthesia. The tumours
were resected, diced and processed by either snap freezing in liquid nitrogen, fixing
in 10% neutral buffered formalin solution for subsequent paraffin embedding,
embedding in OCT, or viably freezing in FCS supplemented with 5% DMSO.
Sample preparation of clinical tumour material. Clinical samples were cryo-
sectioned in 30 µm slices using the Leica CM 3050 S cryostat. Tissue sections were
fixed in a two-step procedure by adding 2 mM DSG for 25 min. In the same
suspension of tissue sections, 1% FA was added for another 20 min without
removal of the DSG. Crosslinking was quenched by the addition of glycine to a
final concentration of 0.25M. Samples were centrifuged for 3 min at 2500 g and the
supernatant was discarded. Tissue pellets were washed twice with cold PBS and
resuspended in 6 ml LB3 buffer (10 mM Tris-HCl (pH 8), 100 mM NaCl, 1 mM
EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, and 0.5% N-lauroylsarcosine), fol-
lowed by tip sonication for 12–20 cycles (30 s on, 1 min off) depending on the
tumour size. The downstream processing was performed as described above (see
RIME method section) and the tissue samples were separated in two parts for the
performance of ERα and IgG RIME pull-down assays. Patient and patient-derived
tissues used in this work were collected under protocol X13-0133,
HREC/13/RPAH/187. HREC approval was obtained through the SLHD (Sydney
Local Health District) Ethics Committee ((Royal Prince Alfred Hospital) zone), and
site-specific approvals were obtained for all additional sites. Written consent was
obtained from all patients prior to collection of tissue and clinical data stored in a
de-identified manner, following pre-approved protocols. All animal procedures
were carried out in accordance to relevant national and international guidelines
and animal protocols approved by the Garvan/St Vincent’s Animal Ethics Com-
mittee (Animal ethics number 15/10).
Immunohistochemistry. FFPE blocks from PDX tumours were sectioned at 4 µm
onto Superfrost Plus slides. Immunohistochemistry was carried out using the Leica
Bond Autostainer. Sections underwent dewaxing, heat induced antigen retrieval
(Leica reagent ER2, 30 mins), and primary and secondary antibody incubations,
using ERα antibody (ab108398, Abcam, 1:500) and the EnVision+ Rabbit sec-
ondary system, respectively. Sections were counterstained with haematoxylin.
Trypsin digestion and TMT labelling. A volume of 10 μL trypsin solution (15 ng/
μl) (Pierce) in 100 mM AMBIC was added to the beads followed by overnight
incubation at 37 °C. A second digestion step was performed the next day for 4 h.
After proteolysis the tubes were placed on a magnet and the supernatant solution
was collected after acidification by the addition of 2 μl 5% formic acid. The
resultant peptides were cleaned with the Ultra-Micro C18 Spin Columns (Harvard
Apparatus) according to manufacturer’s instructions. The peptide samples were
dried with speedvac, reconstituted in 100 μl 0.1 M TEAB (triethylammonium
bicarbonate) and labelled using the TMT-10plex reagents (Thermo Fisher) with a
randomised design. The peptide mixture was fractionated with Reversed-Phase
cartridges at high pH (Pierce #84868). Nine fractions were collected using different
elution solutions in the range of 5–50% ACN.
For the total proteome analysis 200 μl of 0.1 M TEAB, 0.1% SDS buffer was
added to each cell pellet followed by probe sonication and boiling at 95 °C. Protein
concentration was estimated with Bradford assay (BIO-RAD-Quick start)
according to manufacturer’s instructions. For each sample, 90 μg of total protein
were reduced for 1 h at 60 °C by the addition of 2 μL 50 mM tris-2-carboxyethyl
phosphine (TCEP, Sigma). Cysteines were blocked for 10 min on the bench with
the addition of 1 μL 200 mM methyl methanethiosulfonate (MMTS, Sigma). For
peptide generation, trypsin (Pierce #90058) solution was added at ratio protein/
trypsin ~30:1 for overnight digestion at 37 °C. The next day peptides were allowed
to react with the TMT-10plex reagents (Thermo Scientific) for one hour. The
reaction was quenched with 8 μL of 5% hydroxylamine (Thermo Scientific) and the
labelled samples were mixed and dried with speedvac concentrator. The TMT mix
was reconstituted and fractionated on a Dionex Ultimate 3000 system at high pH
using the X-Bridge C18 column (3.5 μm 2.1 × 150 mm, Waters) with 1% gradient.
UV signal was recorded at 280 and 215 nm and fractions were collected in a peak
dependent manner.
LC-MS analysis. Peptide fractions were analysed on a Dionex Ultimate 3000
UHPLC system coupled with the nano-ESI Fusion Lumos (Thermo Scientific).
Samples were loaded on the Acclaim PepMap 100, 100 μm× 2 cm C18, 5 μm, 100 Ȧ
trapping column with the ulPickUp injection method using the loading pump at 5
μL/min flow rate for 10 min. For the peptide separation the EASY-Spray analytical
column 75 μm× 25 cm, C18, 2 μm, 100 Ȧ column was used for multi-step gradient
elution. Mobile phase (A) was composed of 2% acetonitrile, 0.1% formic acid and
mobile phase (B) was composed of 80% acetonitrile, 0.1% formic acid. The elution
method at flow rate 300 nL/min included the following: for 95 min gradient up to
45% (B), for 5 min gradient up to 95% (B), for 8 min isocratic 95% (B), for 2 min
down to 5% (B), for 10 min isocratic equilibration 5% (B) at 40 °C. For the clinical
sample analysis, a longer gradient separation was used as follows: for 160 min
gradient up to 40% (B), for 10 min gradient up to 95% (B), for 8 min isocratic 95%
(B), for 2 min down to 5% (B), and for 10 min isocratic equilibration 5% (B). The
Lumos was operated in a data-dependent mode for both MS2 and SPS-MS3
methods. The full scans were performed in the Orbitrap in the range of 380–1500
m/z at 120 K resolution. The MS2 scans were performed in the ion trap with
collision energy 35%. Peptides were isolated in the quadrupole with isolation
window 0.7 Th. The 10 most intense fragments were selected for Synchronous
Precursor Selection (SPS) HCD-MS3 analysis with MS2 isolation window 2.0 Th.
The HCD collision energy was set at 55% and the detection was performed with
Orbitrap resolution 60k and in scan range 110–400m/z.
Data processing and interpretation. The collected CID tandem mass spectra
were processed with the SequestHT search engine on the Proteome Discoverer
2.1 software for peptide and protein identifications. The node for SequestHT
included the following parameters: Precursor Mass Tolerance 20 ppm, Fragment
Mass Tolerance 0.5 Da, Dynamic Modifications were Oxidation of M (+15.995
Da), Deamidation of N, Q (+0.984 Da) and Static Modifications were TMT6plex at
any N-Terminus, K (+229.163 Da) for the quantitative data. Methylthio at C
(+45.988) was included for the total proteome data. The Reporter Ion Quantifier
node included a TMT 6plex (Thermo Scientific Instruments) Quantification
Method, for MS3 scan events, HCD activation type, integration window tolerance
20 ppm and integration method Most Confident Centroid. The consensus work-
flow included S/N calculation for TMT intensities and the level of confidence for
peptide identifications was estimated using the Percolator node with decoy data-
base search. Strict FDR was set at q-value < 0.01.
Bioinformatics Analysis. We developed an R package (qPLEXanalyzer) to per-
form downstream data analysis. All analyses were performed using only unique
peptides identified with high confidence (peptide FDR < 1%) across all experi-
ments. Peptide-level signal-to-noise (S/N) TMT values were corrected for equal
loading across samples using different normalisation approaches based upon the
experiment type. For the regression-based correction, unique peptides were
aggregated and proteins identified in all the experiments were kept for further
analysis. The normalisation on the bait protein level was carried out at protein level
using log2 row-mean scaled values. To filter-out non-specific proteins, a limma-
based differential analysis was performed comparing ER and IgG control samples.
In the regression analysis, the ERα profile was used as the independent variable (x)
and the profile of any other protein as the dependent variable (y) excluding the IgG
controls. The residuals of the y= ax+ b linear model represent the protein
quantification profiles that are not driven by ERα amount in the pull-down. More
details on the normalisation methods used can be found in Supplementary Note 2.
The identification of differentially bound proteins was carried out using the limma-
based analysis. A multiple testing correction was applied on p-value using the
Benjamini–Hochberg method to control the FDR.
Code availability. The qPLEXanalyzer and qPLEXdata R packages are available at
(https://doi.org/10.5281/zenodo.1237825). Both pipelines are described in detail in
Supplementary Notes 1 and 2.
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Data availability. RNA-seq data have been deposited in NCBI’s Gene Expression
Omnibus69 and are accessible through GEO Series accession number GSE104872.
The mass spectrometry proteomics data have been deposited to the ProteomeXchange
Consortium via the PRIDE70 partner repository with the data set identifier
PXD007968. All other data supporting the findings of this study are available from the
corresponding authors on reasonable request.
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